References
- World Health Organization Director-General’s remarks at the media briefing on 2019-nCoV on 11 February 2020. [cited 2021 Mar 10]. Available from: http://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020
- World Health Organization. Coronavirus disease (COVID-19) dashboard. 2020 [cited 2021 Mar 14]. Available from: https://covid19.who.int
- Li J, Huang DQ, Zou B, et al. Epidemiology of COVID-19: a systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. J Med Virol. 2021;93(3):1449–1458.
- World Health Organization. Novel coronavirus (2019-nCoV). Situation Report 22. 2020 [cited 2021 May 4]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
- US Food and Drug Administration. Emergency use authorization for vaccines to prevent COVID-19: guidance for industry. [cited 2021 Mar 10]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/emergency-use-authorization-vaccines-prevent-covid-19
- WHO Target Product Profiles for COVID-19 Vaccines. Apr 2020 [cited 2021 Mar 10]. Available from: htps://www.who.int/publications/m/item/who-target-product-profiles-for-covid-19-vaccines
- US Food and Drug Administration. Development and licensure of vaccines to prevent COVID-19: guidance for industry. [cited 2021 Mar 10]. Available from: https://www.fda.gov/media/139638/download
- Gated Foundation. Gates Foundation Ideas dashboard [Internet]. Gates Foundation; 2020 [cited 2021 Aug 23]. Available from: https://www.gatesfoundation.org/ideas/articles/coronavirus-funding-additional-250-million-suzman
- Gavi Vaccine Alliance. COVAX dashboard [Internet]. GAVI; 2021 [cited 2021 Aug 24]. Available from: https://www.gavi.org/news/media-room/republic-Korea-pledges-us-200-million-support-lower-income-economies-through-gavi
- Edwards K, Wa O. No Coronavirus disease 2019 (COVID-19): vaccines to prevent SARSCoV- 2 infection. UptoDate. [cited 2021 Mar 10]. Available from: https://www.uptodate.com/contents/covid-19-vaccines-to-prevent-sars-cov-2-infection
- Gao Q, Bao L, Mao H, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020;369(6499):77–81.
- Ramasamy MN, Jessop LJ. CoronaVac: more data for regulators and policy makers. Lancet. 2021;398(10296):186–188.
- Lipsitch M, Grad YH, Sette A, et al. Cross-reactive memory T cells and herd immunity to SARS-CoV-2. Nat Rev Immunol. 2020;20:709–713.
- Sadoff J, Le Gars M, Shukarev G, et al. Interim Results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine. N Engl J Med. 2021;384(19):1824–1835.
- TC Sağlık Bakanlığı 13.03.2009/7943-2009/18 sayılı ASİE Daimi Genelgesi. 2009. Available from: https://www.saglik.gov.tr/TR,11136/asi-sonrasi-istenmeyen-etkiler-genelgesi-2009.html
- Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(2):181–192.
- Wu Z, Hu Y, Xu M, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(6):803–812.
- Xia S, Duan K, Zhang Y, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA. 2020;324(10):951–960.
- Che Y, Liu X, Pu Y, et al. Randomized, double-blinded and placebo-controlled phase II trial of an inactivated SARS-CoV-2 vaccine in healthy adults. Clin Infect Dis. 2020;2020:ciaa1703.
- Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021;21(1):39–51.
- Tanriover MD, Doğanay HL, Akova M, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021;398(10296):213–222.
- Squarcione S, Sgricia S, Biasio LR, et al. Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects. Vaccine. 2003;21(11–12):1268–1274.
- Ghosh S, Klein RS. Sex drives dimorphic immune responses to viral infections. J Immunol. 2017;198(5):1782–1790.
- Katsuyama YT. Willingness to receive COVID-19 vaccination in Japan. Vaccines (Basel). 2021;9(1). DOI:https://doi.org/10.3390/vaccines9010048
- Karlsson LC, Soveri A, Lewandowsky S, et al. Fearing the disease or the vaccine: the case of COVID-19. Pers Individ Dif. 2021;172:110590.
- Wood RA, Berger M, Dreskin SC, et al. An algorithm for treatment of patients with hypersensitivity reactions after vaccines. Pediatrics. 2008;122(3):e771–7.
- Wood RA. Allergic reactions to vaccines. Pediatr Allergy Immunol. 2003;24(6):521–526.
- Barbaud A, Deschildre A, Waton J, et al. Hypersensitivity and vaccines: an update. Eur J Dermatol. 2013;23(2):135–141.
- DiMiceli L, Pool V, Kelso JM, et al. Vaccination of yeast sensitive individuals: review of safety data in the US vaccine adverse event reporting system (VAERS). Vaccine. 2006;24(6):703–707.
- Soriano A, Nesher G, Shoenfeld Y. Predicting post-vaccination autoimmunity: who might be at risk? Pharmacol Res. 2015;92:18–22.